Boyds Acquires New Cambridge Office to Support Rapid Growth
Boyds, the drug development consultancy which helps pharmaceutical companies translate great science into marketable medicines for patient benefit, has relocated into new premises in Cambridge.
The company has invested in excess of £0.5m in the purchase and complete refurbishment of a 1700 sq ft building located at South Cambridge Business Park in Sawston.
Boyds was previously located in Cottenham, a village on the outskirts of the city, and its head office will remain in Crewe, Cheshire.
Professor Alan Boyd, CEO and founder of Boyds said the team had outgrown its former property after a period of swift growth.
He said: “Our team has grown significantly in the last 12 months and we needed more space so we could futureproof our building for further new capacity in the months and years ahead.
“We remain in a prime location, close to academic groups, start-up hubs and industry, with several science parks within a five-mile radius.
“We also now have a dedicated meeting room facility that can support large client meetings and seminars.”
Professor Boyd said Boyds was committed to Cambridge as the city continues to be a thriving scientific hub that is recognised globally for its excellence in innovative research, and can be easily reached from London.
He added: “Cambridge is an ideal location for Boyds as it is optimally aligned with our goal to provide expert consultancy services for clients globally who are focusing on innovative products and treatment approaches.”
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE
Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug ScreeningNews
A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery.READ MORE